-
Use of budget savings from patent expiration of cancer drugs to improve affordability and accessibility
Seung Mi Lee et al.,
BMC Health Services Research, 2021
-
The Costs of Delayed Generic Drug Entry: Evidence from a Controversial Prostate Cancer Drug Patent
David Miller et al.,
Journal of General Internal Medicine, 2021
-
Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome-positive leukemias
Kota V et al. Leuk Res. 2021,
Brought to you by Pfizer Medical affairs
-
Opportunities and Challenges for Biosimilars: What's on the Horizon in the Global Insulin Market?
Lisa S. Rotenstein et al.,
Clin Diabetes, 2012
-
Factors that have an Impact on Abbreviated New Drug Application (ANDA) Submissions
Saranrat Wittayanukorn et al.,
Therapeutic Innovation & Regulatory Science, 2020